Gabapentin for Muscle Spasms: How It Works & Side Effects

Gabapentin is not approved by the FDA specifically for muscle spasms, but doctors prescribe it off-label for spasticity and muscle cramps with enough frequency that it has become one of the more common non-opioid options in pain and rehabilitation clinics. The drug works through a slow-acting mechanism involving calcium channels in the nervous system rather than through direct muscle relaxation, which makes its profile quite different from older antispasmodics like baclofen or diazepam. The evidence behind this use is real but uneven, and the side-effect picture deserves more attention than it typically gets.

How Gabapentin Actually Works

The name “gabapentin” sounds like it should do something with GABA, the brain’s main calming neurotransmitter, but that is mostly a historical accident of how the drug was designed. Gabapentin has no meaningful activity at GABA receptors and does not affect GABA uptake in the brain.¹ Instead, it binds to a specific part of voltage-gated calcium channels, the alpha-2-delta subunit, in a way that disrupts how those channels get trafficked to the surface of nerve cells. When gabapentin is present over time, fewer calcium channels end up on nerve cell membranes. Fewer channels means less calcium flows in when the nerve fires, which dampens the release of excitatory signaling molecules.²

This matters for muscle spasms because spasticity and cramps involve overexcitable nerve circuits. In spinal cord injuries, for example, the normal inhibitory signals from the brain are cut off, and spinal motor neurons fire too easily. In multiple sclerosis, damaged nerve pathways can produce similar runaway excitability. By turning down the volume on calcium-dependent signaling, gabapentin makes those nerve circuits less trigger-happy.

One practical consequence of this mechanism is that gabapentin does not work immediately. Because it needs to disrupt the trafficking of calcium channels over days, a single dose does very little. The therapeutic effect builds over the first one to two weeks of consistent use. Researchers have confirmed this in lab settings: gabapentin inhibits calcium currents only with chronic exposure, not with acute application.² If you take a single dose hoping to stop a cramp in progress, you will likely be disappointed.

What the Evidence Says for Spasticity

Most of the clinical research on gabapentin and muscle spasms falls into two buckets: spasticity from neurological conditions and ordinary muscle cramps. The evidence is stronger for the first category, though still limited by small study sizes.

For spasticity caused by multiple sclerosis, a placebo-controlled randomized trial found that gabapentin produced statistically significant improvements across several measures, including spasm severity, interference with daily function, painful spasms, and physician-assessed muscle tone.³ Case reports have described patients whose spasticity dropped enough to regain meaningful walking ability. In one account, a patient who could only take a few steps with a walker before treatment was walking 75 to 100 meters with the same walker after three months on gabapentin. A second patient went from needing a cane to walking long distances unaided.⁴

For spinal cord injury, the picture is more nuanced. In one controlled trial, group-level results at the initial dose did not reach statistical significance. But individual patients showed improvements that were detectable on surface EMG even when they were not obvious in a clinical exam, and when doses were increased during an open-label extension (up to 3,600 mg per day), the participants experienced clinically meaningful reductions in spasticity.⁵ Animal research has corroborated this, showing that gabapentin reduced both stretch-related and pain-related spastic reflexes after severe spinal cord injury.⁶

A recurring theme across this research is that higher doses tend to work better, with the effect appearing dose-dependent up to at least 3,600 mg per day. Researchers studying spinal cord injury patients specifically noted a quantitative dose-response relationship and recommended that future controlled trials test higher doses than the initial studies used.⁵

What About Ordinary Muscle Cramps

Muscle cramps that strike out of nowhere in the calf at 3 a.m. are a different beast from neurological spasticity, but gabapentin has been tested for those too. An open-label trial gave gabapentin to patients with frequent muscle cramps at doses between 600 and about 900 mg per day. Within two weeks at 600 mg daily, cramp frequency and severity dropped, along with the sleep disruption cramps were causing. After one month, roughly two-thirds of patients were in complete remission, and after three months, cramps had disappeared in every patient studied. Researchers also measured the electrical threshold needed to trigger a cramp in the lab and found that gabapentin returned it to normal values.⁷

Those results are encouraging, but the study was open-label, meaning there was no placebo group. Muscle cramps respond strongly to placebo, so these findings need to be interpreted cautiously. The researchers themselves flagged this limitation. Still, the neurophysiological data showing a change in cramp threshold adds some objectivity beyond patient self-report.

How Gabapentin Compares to Other Options

A network meta-analysis that pooled data across studies of oral drugs for spasticity from various causes found that gabapentin was the intervention most likely to be ranked first for improving spasticity, with a probability of about 49%. That said, the drugs with the strongest statistical evidence for effectiveness were eperisone, diazepam, and baclofen, which all reached significance in the network analysis. Eperisone had the highest overall utility ranking.⁸

In practice, the choice between these drugs often comes down to side-effect profiles rather than efficacy alone. Baclofen is the most established option for spasticity but can cause significant sedation and carries a serious withdrawal risk. Diazepam works well but brings all the baggage of a benzodiazepine: dependence, cognitive impairment, and fall risk, especially in older adults. Tizanidine is another common choice, with a sedation profile that some patients find useful at bedtime but limiting during the day. Gabapentin slots into this picture as an alternative that may be better tolerated in some individuals, with the added benefit of addressing neuropathic pain when pain and spasms coexist.

Side Effects You Should Know About

Gabapentin’s reputation as a mild, well-tolerated drug has been somewhat oversold. The most common side effects are dizziness, drowsiness, and peripheral edema (swelling in the legs and feet). In pooled data from three clinical trials in patients with nerve pain, dizziness affected about one in five patients at lower doses, while drowsiness affected about one in seven. The swelling issue is more tied to higher doses: patients on 1,800 mg per day or more had a swelling rate of about 7.5%, compared with under 2% for those on lower doses or placebo.⁹

An interesting wrinkle in that same pooled analysis: dizziness and drowsiness were actually more common at lower doses than at higher ones. The rates at 1,800 mg or above were comparable to placebo. This may reflect the fact that patients who tolerate the drug well are the ones who continue to higher doses, while those who get dizzy drop out earlier. It is not evidence that higher doses are inherently safer.

For older adults, the fall risk is the side effect that deserves the most attention. A retrospective study of older adults with cognitive impairment found that starting gabapentin was associated with roughly 2.5 times the odds of falling within two years compared with not taking the drug.¹⁰ A separate study in older adults who started out cognitively normal found a similar increase in fall risk and also identified a link between starting gabapentin and declining cognitive and functional scores over the following year or two.¹¹ These are observational findings and do not prove gabapentin caused the decline, but combined with the dizziness and sedation profile, they warrant caution in prescribing to elderly patients, particularly those who already have balance issues or live alone.

Why Kidney Function Matters

Gabapentin is unusual among medications because it is not processed by the liver at all. It passes through the body and is excreted entirely by the kidneys in its original form.¹² This makes it safer for people with liver problems but creates a real hazard for anyone with impaired kidney function. If the kidneys cannot clear the drug efficiently, blood levels climb and side effects intensify.

Case reports have documented patients with chronic kidney disease who developed severe involuntary jerking movements (myoclonus) after modest dose increases of gabapentin.¹³ Dose adjustments based on kidney function are essential, and anyone with known kidney impairment should discuss this explicitly with their prescriber rather than assuming standard dosing guidelines apply.

Gabapentin also has an unusual absorption characteristic: it relies on a specific amino acid transporter in the intestine rather than being passively absorbed. This transporter becomes saturated at higher doses, meaning that doubling the dose does not double the amount of drug that actually gets into the bloodstream.¹² Splitting the daily dose into more frequent, smaller doses can improve absorption. One study found that dividing the same daily amount into four doses instead of three reduced side effects like dizziness, unsteadiness, drowsiness, and nausea while maintaining pain relief.¹⁴

The Opioid Interaction Problem

Gabapentin is frequently prescribed alongside opioids, often with the intention of reducing the opioid dose needed for pain control. But the combination carries a serious and underappreciated risk. A large population-based study found that being co-prescribed gabapentin and opioids was associated with roughly 1.5 times the odds of opioid-related death compared with taking opioids alone, after adjusting for other factors. The risk was dose-dependent: moderate and high doses of gabapentin each carried about a 60% increase in the odds of opioid-related death.¹⁵

The underlying issue is that gabapentin can contribute to respiratory depression, the mechanism by which opioid overdoses kill.¹⁶ In surgical patients, gabapentinoid use was associated with roughly 1.7 times the rate of respiratory complications and opioid-related adverse events.¹⁷ This does not mean the two drugs should never be used together, but it does mean that the combination requires careful monitoring and honest conversations about the risks, especially for patients already on higher opioid doses or those with sleep apnea or other breathing issues.

Reviews of gabapentin’s broader off-label landscape have raised concerns that the drug may not be as benign as its early reputation suggested, and that evidence for many off-label uses ranges from modest to nonexistent.¹⁸

Stopping Gabapentin Safely

Many people and some clinicians still think of gabapentin as a drug you can simply stop taking when you are done with it. That is not always the case. Withdrawal symptoms have been documented even with gradual tapers, particularly in older adults. Symptoms can resemble alcohol or benzodiazepine withdrawal: anxiety, sweating, tremor, and in some cases seizures. One case report described debilitating withdrawal symptoms in an elderly patient despite a week-long taper, leading the authors to recommend that gabapentin tapers follow a schedule similar to benzodiazepine tapers, meaning slow reductions over weeks to months rather than days.¹⁹

In patients who develop severe dependence, the taper process can be remarkably drawn out. One documented case required 18 months to discontinue gabapentin fully, using tiny dose reductions of as little as 5 mg at a time toward the end.²⁰ That patient had a history of alcohol use disorder, which may have contributed to the severity, but the case illustrates that gabapentin dependence is not merely theoretical. If you have been on gabapentin for more than a few weeks, do not stop abruptly without medical guidance.

Gabapentin for Children With Dystonia

One population where gabapentin has shown a somewhat different pattern of use is children with dystonic cerebral palsy. In these children, involuntary sustained muscle contractions cause pain, disturb sleep, and make seating and daily care difficult. A study of 69 children, most of whom were non-ambulatory, found that gabapentin significantly improved dystonia severity, sleep quality and duration, mood, pain, general muscle tone, and seating tolerance. The doses needed for dystonia were considerably higher than those used for pain alone: roughly 18 mg per kilogram per dose for dystonia compared with about 8 mg per kilogram for pain relief without dystonia.²¹

A pilot feasibility study in children with dystonic cerebral palsy found improvements in parents’ ratings of their child’s performance in daily activities and overall comfort after 12 weeks. Side effects were common, though: eight of 13 participants experienced at least one, with gastrointestinal issues, drowsiness, weakness, and behavioral changes being the most frequent. Most were mild to moderate and resolved by the study’s end, but one child withdrew due to lethargy, weakness, and low mood, and another experienced behavioral and mood changes judged possibly related to the medication.²² The behavioral side effects in children are worth flagging because they do not feature as prominently in adult studies and may catch families off guard.

When Gabapentin Makes Sense and When It Does Not

Gabapentin occupies a specific niche for muscle spasms. It is not a rescue medication for an acute cramp. Its slow onset and need for steady dosing mean it is suited to chronic or recurring spasticity and cramp patterns, not one-off episodes. It works best when nerve overexcitability is a major driver of the problem, which is why the evidence is strongest in conditions like MS, spinal cord injury, and dystonia, where damaged or disconnected nerve pathways are clearly responsible.

For someone whose muscle spasms are caused by dehydration, electrolyte imbalances, overexertion, or simple nighttime leg cramps, gabapentin is rarely the first thing a doctor should reach for. Addressing the underlying cause, or trying simpler interventions first, makes more sense. But when first-line options have failed, or when spasms coexist with neuropathic pain that gabapentin can also help address, the drug becomes a reasonable addition to the treatment plan.

The dosing sweet spot appears to differ substantially depending on the condition. Ordinary muscle cramps may respond to as little as 600 to 900 mg per day. Spasticity from neurological injury often requires 1,200 to 3,600 mg per day. Dystonia in children may demand even higher weight-based doses. Starting low and increasing gradually over weeks remains the standard approach, both to find the effective dose and to minimize the dizziness and drowsiness that tend to be worst during the first week or two of treatment. Splitting doses into four daily administrations rather than three can reduce side effects by taking advantage of the drug’s saturable absorption in the gut, producing a smoother blood level throughout the day.